Banner
  • Home
  • Resources
  • Knowledge
  • A Comprehensive Analysis of U.S. FDA-Approved Fluorinated Drugs: Structural Advantages, Applications, and Industry Insights

CONTACT US

Tel:
Fax:
Address:
Email: For product inquiries or a copy of our product catalog, please use our online system or send an email to .

A Comprehensive Analysis of U.S. FDA-Approved Fluorinated Drugs: Structural Advantages, Applications, and Industry Insights

Why Are Fluorinated Drugs Essential in Modern Pharmacotherapy?

The integration of fluorine atoms within active pharmaceutical ingredients remains a potent technique in medicinal chemistry that improves their pharmacological attributes. The incorporation of one or more fluorine atoms and fluorinated groups (CF3 or -F) into drug structures makes these drugs essential in development because of fluorine's special electronegativity, improved metabolic stability, and increased lipophilicity. In recent years, the U.S. Food and Drug Administration (FDA) has approved more new molecular entities (NMEs) that feature fluorine within their molecular structures across multiple therapeutic areas, including oncology and infectious diseases, as well as neurological disorders and cardiovascular conditions.

Alfa Chemistry functions as a leading provider of fluorinated pharmaceutical intermediates and APIs by supplying researchers and manufacturers with a broad range of high-purity fluorinated building blocks to fulfill industrial requirements.

How Has the FDA's Fluorinated Drug Approval Landscape Evolved Between 2018 and 2022?

Between 2018 and 2022, the FDA approved 54 fluorinated small-molecule drugs, accounting for approximately 30% of all small-molecule NMEs during that period. This trend reflects the ongoing shift toward designing molecules with tailored physicochemical and pharmacokinetic properties enabled by strategic fluorination. Among these approvals, drugs containing fluorinated aromatic rings, trifluoromethyl (CF3) groups, and fluoroalkyl chains dominated. These fluorinated fragments are not merely structural novelties but critical to drug performance - improving membrane permeability, receptor binding affinity, and resistance to metabolic degradation.

Fig.1 U.S. FDA-approved fluorinated drugsFigure 1. FDA-approved fluorinated drugs[1].

Notably, the number of fluorinated drugs peaked in 2020, corresponding to the urgent development of therapeutics during the COVID-19 pandemic. Compounds such as Remdesivir (Veklury), a fluorinated nucleotide analog antiviral, exemplify how fluorinated structures can rapidly be adapted for emerging threats.

Table 1: U.S. FDA-Approved fluorinated drugs (2018-2022)[1].

Therapeutic Areas Drug Approval Date Composition Indication Drug Mechanism
Anti-cancerErleada2/14/2018ApalutamideProstate cancerAndrogen receptor inhibitor
Mektovi6/27/2018BinimetinibBRAF V600E– or V600K–positive metastatic melanoma (in combination with Braftovi)MEK1/2 inhibitor
Braftovi6/27/2018EncorafenibBRAF V600E– or V600K–positive metastatic melanoma (in combination with Mektovi)BRAF inhibitor
Tibsovo7/20/2018IvosidenibAcute myeloid leukemiaIDH1 inhibitor
Vizimpro9/27/2018DacomitinibNon-small-cell lung cancerIrreversible EGFR inhibitor
Lorbrena11/2/2018LorlatinibALK-positive metastatic non-small-cell lung cancerALK inhibitor
Talzenna10/16/2018TalazoparibBreast cancer with germline BRCA mutationsPARP inhibitor
Vitrakvi11/26/2018LarotrectinibNTRK gene fusion–positive solid tumorsTRK inhibitor
Piqray5/24/2019AlpelisibBreast cancerPI3Ka inhibitor
Xpovio7/3/2019SelinexorMultiple myelomaNuclear export inhibitor
Turalio8/2/2019PexidartinibSymptomatic tenosynovial giant-cell tumorsCSF1R, KIT, and FLT3-ITD inhibitor
Rozlytrek8/15/2019EntrectinibNon-small-cell lung cancer whose tumors are ROS1 positiveROS1 and NTRK inhibitor
Ayvakit1/9/2020AvapritinibGastrointestinal-stromal tumorPDGFRA and KIT inhibitor
Isturisa3/6/2020OsilodrostatCushing's disease in adultsCortisol synthesis inhibitor
Koselugo4/10/2020SelumetinibNeurofibromatosis type 1, a genetic disorder that causes tumors to grow on nervesMEK1/2 inhibitor
Pemazyre4/17/2020PemigatinibCholangiocarcinoma, a rare form of cancer that forms in bile ductsFGFR inhibitor
Tabrecta5/6/2020CapmatinibNon-small-cell lung cancerMET inhibitor
Qinlock5/15/2020RipretinibGastrointestinal-stromal tumorsKIT and PDGFRA kinase inhibitor
Cerianna5/20/2020Fluoroestrdiol F18Diagnostic imaging agent for certain patients with breast cancerRadiodiagnostic
Inqovi7/7/2020Decitabine and cedazuridineMyelodysplastic syndromesNucleoside metabolic inhibitor and cytidine deaminase inhibitor
Gavreto9/4/2020PralsetinibNon-small-cell lung cancerRET fusion inhibitor
Orladeyo12/4/2020BerotralstatPrevention of hereditary angioedemaPlasma kallikrein inhibitor
Orgovyx12/18/2020RelugolixProstate cancerGnRH receptor antagonist
Ukoniq2/5/2021UmbralisibMarginal zone lymphoma or follicular lymphomaKinase inhibitor
Pepaxto2/26/2021Melphalan flufenamideRelapsed or refractory multiple myelomaDNA alkylation
Pylarify5/26/2021Piflufolastat F-18Identification of lesions positive for prostate-specific membrane antigen in people with prostate cancerBinds to malignant prostate cancer cells
Lumakras5/28/2021SotorasibNon-small-cell lung cancerKRAS G12C inhibitor
Welireg8/13/2021BelzutifanVon Hippel-Lindau diseaseHypoxia-inducible factor-2α inhibitor
Scemblix10/29/2021AsciminibPhiladelphia chromosome–positive chronic myeloid leukemiaKinase inhibitor
Krazati12/12/2022AdagrasibKRAS G12C–mutated non-small-cell lung cancerIrreversible inhibitor of KRAS G12C
Infectious diseasesBiktarvy2/7/2018Bictegravir Sodium, Emtricitabine and Tenofovir alafenamide fumarateHIV infectionIntegrase strand transfer inhibitor, two HIV nucleoside analog reverse transcriptase inhibitors
Akynzeo4/19/2018Netupitant and palonosetronNauseaNK1 receptor antagonist and 5-HT3 receptor antagonist
TPOXX7/13/2018TecovirimatSmallpoxOrthopoxvirus VP37 envelope wrapping protein inhibitor
Krintafel7/20/2018TafenoquineMalaria relapse prevention8-Aminoquinoline antiparasitic
Xerava8/27/2018EravacyclineComplicated intra-abdominal infectionsAntibiotic, binds 30S ribosomal subunit to block protein synthesis
Pifeltro8/30/2018DoravirineHIV-1 infectionAntiviral, reverse transcriptase inhibitor
Xofluza10/24/2018Baloxavir marboxilInfluenzaAntiviral inhibitor of influenza polymerase acidic protein
Pretomanid8/14/2019PretomanidTreatment-resistant tuberculosisNitroimidazooxazine antimycobacterial
Cabenuva1/21/2021Cabotegravir and RilpivirineHIVHIV-1 antiretrovirals
Voquezna5/3/2022Vonoprazan, Amoxicillin, and CarithromycinHelicobacter Pylori InfectionProton pump inhibitor and antimicrobials
Vivjoa4/26/2022OteseconazoleRecurrent vulvovaginal candidiasis14α-Demethylase inhibitor
Sunlenca12/22/2022LenacapavirHIV infections in adults that cannot be successfully treated with other available treatmentsHIV-1 antiretroviral agent
Central nervous system (CNS) disordersMayzent3/26/2019SiponimodRelapsing forms of multiple sclerosisSelective sphingosine 1-phosphate receptor modulator
Fluorodopa F-1810/10/2019Fluorodopa F-18Diagnostic for Parkinson's diseasePositron-emission tomography
Reyvow10/11/20219LasmiditanAcute migraines5-HT1F receptor agonist
Caplyta12/20/2019Lumateperone tosylateSchizophreniaUnknown
Dayvigo12/20/2019LemborexantInsomniaOrexin receptor antagonist
Ubrelvy12/23/2019UbrogepantAcute migrainesCGRP receptor antagonist
Nurtec ODT2/27/2020RimegepantMigraineCalcitonin gene-related peptide receptor antagonist
Tauvid5/28/2020Flortaucipir F18Alzheimer's disease diagnosticRadiodiagnostic
Qulipta9/28/2021AtogepantEpisodic migrainesCalcitonin gene–related peptide receptor antagonist
Verquvo1/19/2021VericiguatChronic heart failureSoluble guanylate cyclase stimulator
Other diseasesSymdeko2/13/2018Tezacaftor and IvacaftorCystic FibrosisCFTR corrector and CFTR potentiator
Tavalisse4/17/2018FostamatinibChronic immune thrombocytopeniaSYK inhibitor
Orilissa7/23/2018Elagolix sodiumEndometriosisGnRH receptor antagonist
Rinvoq8/16/2019UpadacitinibRheumatoid arthritisJAK inhibitor
Trikafta10/21/2019Tezacaftor, Ivacaftor and ElexacaftorCystic FibrosisCCFTR corrector, CFTR potentiator and CFTR corrector
Tavneos10/7/2021AvacopanSevere active antineutrophil cytoplasmic autoantibody–associated vasculitisC5a receptor antagonist

What Structural Benefits Do Fluorine Atoms Offer in Drug Design?

Fluorine atoms influence molecular behavior in several scientifically advantageous ways:

Effect Mechanism Therapeutic Benefit
Increased lipophilicityFluorine enhances hydrophobic interactionsImproved membrane permeability and oral bioavailability
Metabolic stabilityC–F bonds resist oxidative degradationLonger half-life, fewer dosing intervals
Enhanced binding affinityAlters pKa, dipole moments, and hydrogen bondingGreater target selectivity and potency
Conformational restrictionInfluences torsional angles in bioactive conformationsBetter receptor fit and efficacy

These properties explain why fluorinated drugs frequently show improved ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles, making them highly favored in preclinical and clinical drug pipelines.

What Infectious Diseases Are Targeted by Fluorinated Pharmaceuticals?

Between 2018 and 2022, twelve FDA-approved fluorinated drugs targeted a broad spectrum of infectious diseases, ranging from HIV and smallpox to malaria and SARS-CoV-2.

  • HIV/AIDS: Biktarvy, Cabenuva, Pifeltro, and Sunlenca serve as multi-mechanistic antiretrovirals. Fluorine improves intracellular half-life and resistance profiles by stabilizing conformational states of integrase and reverse transcriptase binding pockets.
  • Smallpox and Viral Infections: TPOXX (Tecovirimat), a VP37 protein inhibitor, exemplifies fluorine-enabled potency against orthopoxviruses. Paxlovid (Nirmatrelvir + Ritonavir), used for COVID-19, utilizes fluorinated moieties to increase protease binding and reduce metabolic degradation.
  • Antifungals and Antimalarials: Brexafemme (Ibrexafungerp) and Krintafel (Tafenoquine) are fluorinated agents offering new mechanisms for fungal and parasitic disease control. Their chemical resilience, partly imparted by fluorine, is critical in resisting enzymatic breakdown and prolonging systemic activity.

Fig.2 Chemical structures of drugs for various types of cancer approved by the US FDA from 2018 to 2022.Figure 2. Chemical structures of drugs approved by the FDA for various types of cancer from 2018 to 2022[1].

Fig.3 Chemical structures of infectious disease drugs approved by the US FDA from 2018 to 2022.Figure 3. Chemical structures of infectious disease drugs approved by the FDA from 2018 to 2022[1].

How Do Fluorinated Functional Groups Influence Drug Behavior?

Fluorinated Moiety Representative Drugs Pharmacokinetic Effect
Aromatic -F or -CF3Drugs 1–8, 10–19, 22–24, 27Improved metabolic stability, increased protein binding affinity
Geminal -CF2Drugs 4, 20, 29Enhanced potency and metabolic resistance
Aliphatic -CF3Drugs 9, 12Reduced microsomal clearance
Vicinal -F2Drug 28Increased stability and potency
Vinylic -FDrug 30Optimized binding while retaining metabolic robustness

These substitutions enhance molecular conformation, binding kinetics, and receptor selectivity. The trifluoromethyl (-CF3) group is particularly effective in modulating lipophilicity and electronic distribution, while gem-difluoro groups help lock bioactive conformations, critical for kinase inhibitors and protease blockers.

Fig.4 Chemical structures of central nervous system drugs approved by the US FDA from 2018 to 2022.Figure 4. Chemical structures of central nervous system drugs approved by the FDA from 2018 to 2022[1].

Fig.5 Chemical structures of drugs for other diseases approved by the US FDA from 2018 to 2022.Figure 5. Chemical structures of drugs approved by the FDA from 2018 to 2022 for other diseases[1].

FAQs about FDA-Approved Fluorinated Drugs

Q1: What makes fluorine such an effective element in drug design?

Fluorine's high electronegativity and small atomic size allow it to influence molecular behavior without adding bulk. It can improve metabolic stability, target binding, and drug absorption.

Q2: How many fluorinated drugs were approved by the FDA from 2018 to 2022?

A total of 42 fluorinated drugs were approved during this period—30 for cancer treatment and 12 for infectious diseases.

Q3: Are any fluorinated drugs used for diagnostic purposes?

Yes, Pylarify and Cerianna are radiopharmaceuticals labeled with fluorine-18 (18F) used in PET imaging for prostate and breast cancers, respectively.

Q4: What types of cancers are treated with fluorinated drugs?

Fluorinated drugs are used to treat prostate, breast, lung, melanoma, leukemia, gastrointestinal stromal tumors, and others.

Q5: How does fluorine affect a drug's metabolism?

Fluorine often reduces enzymatic degradation, increases the drug's half-life, and enhances bioavailability by blocking metabolic hotspots.

Q6: Can fluorinated drugs combat viral infections like HIV or COVID-19?

Yes, drugs like Biktarvy, Sunlenca, and Paxlovid are fluorinated and have demonstrated efficacy against HIV and SARS-CoV-2.

Q7: What role does Alfa Chemistry play in fluorinated drug development?

Alfa Chemistry supplies fluorinated intermediates, radiolabeling precursors, and custom synthesis services critical to developing next-generation fluorinated drugs.

Reference

  1. Ali S., et al. Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022). European Journal of Medicinal Chemistry. 2023, 256, 115476.

How Alfa Chemistry can help you:

Online Inquiry

If you have any questions about our company, please use the form below to contact us.

Verification code
Inquiry

For any inquiry, question or recommendation, please fill out the following form.

Verification code
Online Inquiry